Savara Inc (SVRA)

$3.6

-0.16

(-4.26%)▲

Live

Performance

  • $3.55
    $3.79
    $3.60
    downward going graph

    1.53%

    Downside

    Day's Volatility :6.46%

    Upside

    5.01%

    downward going graph
  • $3.12
    $5.70
    $3.60
    downward going graph

    13.47%

    Downside

    52 Weeks Volatility :45.35%

    Upside

    36.84%

    downward going graph

Returns

PeriodSavara IncIndex (Russel 2000)
3 Months
-18.61%
0.0%
6 Months
-20.0%
0.0%
1 Year
18.24%
0.0%
3 Years
149.01%
-23.0%

Highlights

Market Capitalization
600.8M
Book Value
$0.74
Earnings Per Share (EPS)
-0.42
PEG Ratio
0.0
Wall Street Target Price
10.79
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-38.8%
Return On Equity TTM
-79.48%
Revenue TTM
1000.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
-29.0M
EBITDA
-80.4M
Diluted Eps TTM
-0.42
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.44
EPS Estimate Next Year
-0.43
EPS Estimate Current Quarter
-0.11
EPS Estimate Next Quarter
-0.1

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Savara Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 199.72%

Current $3.60
Target $10.79

Technicals Summary

Sell

Neutral

Buy

Savara Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Savara Inc
Savara Inc
-18.44%
-20.0%
18.24%
149.01%
149.01%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Savara Inc
Savara Inc
NA
NA
0.0
-0.44
-0.79
-0.39
NA
0.74
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Savara Inc
Savara Inc
Buy
$600.8M
149.01%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Savara Inc

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 66.9%

Institutional Holdings

  • NEA Management Company, LLC

    14.87%

  • Bain Capital Life Sciences Investors, LLC

    8.85%

  • TCG Crossover Management, LLC

    7.51%

  • Nantahala Capital Management, LLC

    6.30%

  • BlackRock Inc

    4.88%

  • Wellington Management Company LLP

    4.26%

Company Information

savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com

Organization
Savara Inc
Employees
37
CEO
Mr. Matthew Pauls J.D., M.B.A.
Industry
Health Technology

Discover More

FAQs